Prima BioMed (ASX:PRR; NASDAQ:PBMD) is a globally active and listed biotechnology company focused on developing novel oncology therapies in the field of immunotherapy. Prima BioMed has a clear strategy to develop and commercialize therapeutic vaccine CVac™ in ovarian cancer with an opportunity to expand to other indications. CVac™ has been tested successfully in two clinical studies and is currently in late stage clinical development in Australia, USA and Europe. The Company’s long term goal is the development of commercial cancer therapies on a worldwide scale.
Prima BioMed is headquartered in Sydney, Australia with additional operational facilities in Germany and the USA.